Match!
Zoltán Kaló
Eötvös Loránd University
176Publications
18H-index
1,454Citations
Publications 178
Newest
#2Anke-Peggy HoltorfH-Index: 1
Last.Zoltán Kaló (ELTE: Eötvös Loránd University)H-Index: 18
view all 6 authors...
In Kuwait, the government is planning to improve the specifications for purchase of medicine and to improve the tendering system intending to slow the growth of the expenditure for medicine and to improve the sustainability of the healthcare system. Multiple Criteria Decision Analysis (MCDA) is a method which can help to assess multiple and sometimes conflicting criteria in the evaluation of the available alternatives. The objective of this initiative was to develop collaboratively a MCDA tool w...
Source
#2Marcell CsanádiH-Index: 6
Last.Zoltán Kaló (ELTE: Eötvös Loránd University)H-Index: 18
view all 12 authors...
This paper provides a systematic description of OnkoNetwork on the six components of the SELFIE conceptual framework for integrated care in multimorbidity to understand how and why OnkoNetwork was implemented and cares (better) for its patients. Because integrated care models are designed and adjusted to their specific local needs and context, those few successful and sustainable models that were established in Central and Eastern European countries represent important benchmarks for other initi...
1 CitationsSource
#1Marcell Csanádi (PTE: University of Pécs)H-Index: 6
#2Piotr Ozieranski (University of Bath)H-Index: 7
Last.Lajos Botz (PTE: University of Pécs)H-Index: 12
view all 6 authors...
Abstract Research on health technology assessment (HTA) from a policy perspective typically examines public HTA bodies, with little attention devoted to how manufacturers develop their evidence submissions. Taking Poland as a crucial case, we explored the market of HTA consultancy firms which assist drug manufacturers in developing these submissions, called HTA reports. We reviewed 318 HTA reports from 2012-2015, data from the Polish National Company Registry, the content of HTA consulting firms...
Source
#1A. Inotai (Semmelweis University)H-Index: 4
#2Zoltán Kaló (Semmelweis University)H-Index: 18
Introduction: There is significant difference in utilisation of patented medicines in the EU, as pharmaceuticals at Western European price levels are usually not cost-effective in Central Eastern E...
Source
#1Cristina Rais (ELTE: Eötvös Loránd University)
#2Zoltán Kaló (ELTE: Eötvös Loránd University)H-Index: 18
Last.Vlad Negulescu (UMFCD: Carol Davila University of Medicine and Pharmacy)
view all 4 authors...
Abstract Health Technology Assessment (HTA) is a complex methodology increasingly used worldwide to make transparent and evidence-based reimbursement decisions for health technologies. This study aims to describe the present environment and future prospects of HTA implementation in Romania based on the opinion of a wide range of national stakeholders. A survey was conducted using a questionnaire already applied previously to design HTA roadmaps for middle-income countries. Survey responses were ...
Source
#1András Harsányi (ELTE: Eötvös Loránd University)H-Index: 6
#2Marcell Csanádi (PTE: University of Pécs)H-Index: 6
Last.András Inotai (ELTE: Eötvös Loránd University)H-Index: 7
view all 6 authors...
ABSTRACTObjectives: Utilization of multisource biological (off-patent originator and its biosimilar) medicines can improve the efficiency of resource allocation by 1) generating savings while maint...
1 CitationsSource
#1A.P. HoltorfH-Index: 1
#2Anke-Peggy HoltorfH-Index: 1
Last.Zoltán Kaló (Semmelweis University)H-Index: 18
view all 4 authors...
Abstract Background Countries with expanding healthcare coverage (CEHCs) increasingly use external reference pricing (ERP) for pharmaceuticals. The ERP policies must aim to optimize efficiency, minimize disturbances, and maximize access to effective therapies for all patients. Objective This research aims to deduce best practices for prudent ERP regulations from past experiences and currently applied policies and to guide policymakers in CEHCs in implementing robust ERP policies. Methods The lit...
Source
#1Olga Löblová (University of Cambridge)H-Index: 6
#2Marcell Csanádi (PTE: University of Pécs)H-Index: 6
Last.Martin McKee (Lond: University of London)H-Index: 107
view all 6 authors...
Abstract Many countries employ “alternative access schemes” (e.g. compassionate use, early access programs, off-label use) that seek to provide patients with access to drugs not included on a positive drug list. These schemes offer flexibility to policy-makers but often lack transparency and clear rules. This ambiguity allows for dynamic responses to weaknesses in the main drug approval and reimbursement systems, but also opportunistic use by the health professionals, industry or patients. Yet, ...
Source
#1Olga Löblová (University of Cambridge)H-Index: 6
#2Marcell Csanádi (PTE: University of Pécs)H-Index: 6
Last.Martin McKee (Lond: University of London)H-Index: 107
view all 6 authors...
Abstract European governments employ sophisticated health technology assessment and regulatory procedures to identify which pharmaceuticals to fund publicly. However, there are persisting demands from patients for those drugs excluded from positive reimbursement lists, leading to the emergence of what are here termed “alternative access schemes”. This paper presents a purposive review of these schemes based on available scholarly and grey literature, illustrated with real-world examples from rec...
1 CitationsSource
#1Tomas Tesar (Comenius University in Bratislava)H-Index: 6
#2Branislav ObsitnikH-Index: 1
Last.Finn Børlum Kristensen (University of Southern Denmark)H-Index: 12
view all 4 authors...
Objectives: The aim of this study was to review the impact of new reimbursement requirements for medicines in the Slovak Republic based on legislation that came into force in January 2018. Methods: The new legislation was reviewed. The reimbursement dossiers for medicines and health technology assessments and appraisals, justifications for reimbursement decisions, final reimbursement decisions, and all aspects of the appeal mechanisms have been transparently published on the website of the Slova...
1 CitationsSource
12345678910